AAV Purification Resource
A lower AAV vg/mL after purification does not necessarily indicate vector degradation. The result should be interpreted by comparing total vector genomes, step-wise recovery, particle integrity, and assay consistency to distinguish true process loss from volume changes or detection artifacts. Common causes include chromatography losses, membrane adsorption, aggregation, residual hold-up, and matrix effects, which can be investigated through AAV purification optimization, AAV titer determination, and rAAV genome copy-number titration.
Direct Answer
A drop in vg/mL after purification does not prove degradation. Purification changes volume, buffer, and composition, so the same total virus can report a different concentration. Total vector genomes and step-wise recovery tell the real story.
For example, 1×1012 vg/mL in 10 mL is 1×1013 total vg; after purification to 5×1011 vg/mL in 15 mL, the total is 7.5×1012 vg — a 50% concentration drop but only a 25% total loss.
The key principle: evaluate purification by total vg and step recovery, not by vg/mL alone.
Concentration changes with volume even when total vg is preserved.
Chromatography, ultrafiltration, and adsorption each remove some virus.
Buffer, salt, and protein changes can shift qPCR or ddPCR results.
Loss Sources
Each unit operation adds a chance for loss. Knowing which step is responsible is the first step to a fix.
| Step | How Loss Occurs | What to Check |
|---|---|---|
| Chromatography capture/elution | Serotype–media mismatch: virus flows through, washes off, or fails to elute | Flow-through, wash, and elution fractions for AAV content |
| Ultrafiltration & buffer exchange | Non-specific membrane adsorption and residual volume in lines | Pre- vs. post-filtration total vg and recovery |
| Aggregation / stability | Buffer, pH, ionic strength, temperature, or dwell time destabilize particles | Particle state, purity, and activity alongside titer |
| Surface adsorption | Virus binds tubing, filters, columns, and collection vessels | Low-concentration and small-volume samples are most affected |
| Detection method | Buffer, salt, and matrix differences shift qPCR/ddPCR | Consistent methods and sample handling before and after |
Compare pre- and post-purification total vg with the same method and sample handling, and confirm standards, dilutions, and calculations are unchanged before blaming the process.
Troubleshooting
Measuring only the harvest and final product cannot reveal where the loss happened. Break the process into steps and measure each.
Establish the starting total vg.
High flow-through means poor capture; residual in elution means incomplete release.
If loss appears only here, focus on membrane and system.
A real total-vg loss, not just a concentration shift.
Aggregation, purity change, or integrity loss can also occur alongside the sharp titer drop.
A drop in potency signals more than a concentration artifact.
Troubleshooting
Trace the process from harvest to final formulation, and combine titer with particle state, purity, integrity, and activity to distinguish normal loss from a real problem.
Use the same method, standards, dilution, and sample handling before and after purification.
Account for volume change to separate concentration shift from real loss.
Measure flow-through, wash, elution, and ultrafiltration to find where AAV is lost.
Confirm it is a total-vg loss, not a concentration or detection shift.
Isolate capture, elution, ultrafiltration, or adsorption as the cause.
Add particle state, integrity, and activity to decide if the loss matters.
Interpretation
Not every titer drop is a failure. Some loss is normal if total recovery and quality remain acceptable. Escalate when loss is large and quality suffers.
vg/mL drops but total vg, recovery, purity, and quality stay acceptable.
A real loss of total vg, not just concentration, requires step localization.
Abnormal particle state, lower integrity, or reduced activity signals a real problem.
If recovery suddenly falls below history, review materials, buffers, media, and conditions.
From Choice to Vector
Creative Biolabs can help you localize and resolve AAV titer loss during purification, from process review to quality testing.
Review the capture, wash, elution, and concentration stages as separate opportunities for vector loss. Compare input and output material at each stage, then adjust conditions against both recovery and impurity removal so a higher yield does not simply carry more unwanted material.
Measure vector genome concentration in the starting material, intermediate fractions, and final product using a consistent assay basis. Calculate total vector genomes from concentration and volume at each point; this mass balance helps separate a true process loss from dilution or a change in assay response.
Assess capsid-content distribution and the integrity of the packaged genome alongside protein and process-related impurities. A stable vg/mL value can conceal changes in total recovery or particle composition, so compare results at equivalent stages and with a documented sampling plan.
Compare a relevant transduction or expression readout before and after purification at a defined dose and time point. If genome titer is preserved but activity falls, investigate whether formulation, handling, or capsid condition changed rather than treating the vg measurement as a complete potency result.
Bring together genome titer, total yield, capsid identity, particle composition, impurity levels, and functional activity for the same lot. Reviewing these measures together helps locate the first divergent process step and decide whether the next action is method confirmation, process adjustment, or additional characterization.
Selected Reading
Buck TM, Wijnholds J. Recombinant adeno-associated viral vectors (rAAV)—vector elements in ocular gene therapy clinical trials and transgene expression and bioactivity assays. International Journal of Molecular Sciences. 2020;21(12):4197. https://doi.org/10.3390/ijms21124197.
Gálvez-Montes C, et al. rAAV production cost analysis: indication-specific cost per dose and reduction strategies. Gene Therapy. 2026. https://www.nature.com/articles/s41434-026-00631-3.
FAQ
Share your process steps, serotype, and readouts. We can help you pinpoint the loss and protect product quality and recovery.
Tell us about your AAV purification question and the decision the data must support. Our scientific team will follow up with a project-specific approach.
Inquiry NowFor research use only. Not intended for any clinical use.
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
